DOT Drug Panel Update

Testing Info

The Department of Transportation (DOT) is making changes to its drug-testing panel effective January, 1st 2018. The new regulation will add hydrocodone, hydromorphone, oxymorphone, and oxycodone.  Methylenedioxyamphetamine (MDEA) will be added as an initial test analyte and methylenedioxyethylamphetamine (MDA) will be removed as a confirmatory test analyte. This change to the DOT drug panel is consistent with the revised HHS Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. Also, employers and Third Party Administrators will no longer be required to submit blind specimens.

DOT Drug Panel

Amphetamines
-MDMA (aka Ecstasy)
-MDEA
-MDA
-Methamphetamine
Opiates
-Codeine
-Morphine
-6-Acetylmorphine (Heroin)
-Hydrocodone
-Hydromorphone
-Oxymorphone
-Oxycodone
Marijuana
-THC Metabolite(s)
Cocaine
-Benzoylmethylecgonine
Phencyclidine (PCP)

The addition of opiates is aimed to address the opioid abuse epidemic in the United States. Department of Transportation companies are not immune to drug abuse and the impairing effects. The updated panel will help the DOT expose a broader range of illegal drugs being used. Overall, this change will improve the safety of transportation industries.

By enrolling in a drug screening program with AMC Drug Testing, your company can stay safe from the opioid epidemic and stay in compliance with federal regulations. We offer both Department of Transportation and drug-free workplace programs.

https://www.federalregister.gov/documents/2017/11/13/2017-24397/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-certain